TGFB1 and Alzheimer disease: AD patients also showed a reduction in the plasma levels of the active (25 kDa) and inactive (50 kDa) forms of TGF-β1 [69, 70] as well as a reduced secretion of TGF-β1 from circulating peripheral blood mononuclear cells [71].